ESPE Abstracts

Recent years have seen rapid changes in the availability of new medical treatments as an adjunct to lifestyle support for adults, children and adolescents living with obesity. Although the GLP1 receptor agonist (RA) liraglutide 3 mg, given by daily subcutaneous injection, has been available for some time, the recent approval of semaglutide 2.4 mg weekly represents a major advance in efficacy. In clinical trials, semaglutide results in weight loss of 15% or more in more than ha...

Obesity increased to alarming prevalence in many Western countries, with an emphasized disproportionate rise in its more severe forms. There is increasing body of evidence that established a tight association between childhood and adolescent obesity with various morbidities and mortality data. The purpose of this presentation is to summarize existing data regarding the association of the presence of obesity in childhood/adolescence and early-onset adverse outcomes in adulthood...

Metabolic and bariatric surgery (MBS) is increasingly being used to manage moderate to severe obesity in adolescents and young adults. In addition to being our most effective strategy at this time to reduce body weight, MBS results in significant improvement of many of the metabolic complications of obesity. This includes a rapid improvement in glycemic control in those with type 2 diabetes, and an improvement in lipid profile, liver function, hypertension, obstructive sleep a...